Akari Therapeutics (AKTX) vs Dyadic International (DYAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Akari Therapeutics (AKTX) over the past year, losing 60.7% versus a loss of 80.1%. Over five years, DYAI leads with a -90.8% price change compared with -99.4% for AKTX. Akari Therapeutics is the larger company by market cap ($18.6 million vs $17.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | DYAI |
|---|---|---|
| Share price | $8.13 | $0.4444 |
| Market cap | $18.58M | $17.80M |
| 1-day change | -5.74% | -2.65% |
| YTD return | -29.67% | -52.72% |
| 1-year return | -80.07% | -60.67% |
| 5-year return | -99.38% | -90.84% |
| EPS (TTM) | $0.00 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $1.60 |
| 52-week low | $3.02 | $0.34 |
| Distance from 52-week high | -79.67% | -72.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | +1137.62% |
| Average volume | 61.08K | 201.91K |
| Shares outstanding | 2.29M | 40.06M |
| Employees | 5 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed AKTX by 19.4 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Healthcare · Biotechnology · 5 employees
AKTX vs DYAI FAQ
Which is bigger, Akari Therapeutics or Dyadic International?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $18.58M compared with $17.80M for Dyadic International (DYAI).
Which stock has performed better over the past year, AKTX or DYAI?
DYAI returned -60.67% over the past 12 months, compared with -80.07% for AKTX (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Dyadic International in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.